



Industry Genomics Network Alliance

ANNUAL REPORT 2023 - 2024

(PART YEAR, 1 JANUARY 2024 TO 30 JUNE 2024)

InGeNA Ltd. ABN 78 673 234 430

CHAIR REPORT

The 2023-2024 year was one of great change for InGeNA with major achievements in our maturity journey along with strengthening and confirming our position as the recognised national body for organisations working in the genomics sector.

This Annual Report focuses on the first six months of InGeNA Limited, an incorporated Company Limited by Guarantee and ACNC registered charity. However, I do want to reflect a little on what led us to this point.



Kathy Campbell

InGeNA was formed as an alliance between industry players to provide a single voice for organisations working in the genomics ecosystem. It has provided an opportunity for organisations of different sizes which work in different sectors (such as diagnostics, therapeutics, data/technology, pathology, consulting) to work together towards increasing adoption of and access to genomics. It does this through developing common policy positions, contributing to national discussions, and through collaboration with others such as other industry bodies, consumer groups, government, healthcare providers and academia.

I took over as Chair at the start of 2023. We undertook a highly consultative strategic refresh to ensure that we have agreed clear and common goals, and can effectively leverage the excellent work already done.

At the same time our hosting organisation advised that they no longer wished to host InGeNA as it was not core business. After much deliberation and consideration of options, the members voted that InGeNA should be established as a not for profit and registered charity. InGeNA Limited was incorporated on 27 November 2023 and commenced trading in January 2024.

continued..

There was a lot of work involved in this process including establishing a Constitution and initial Board both approved by Members, setting up bank accounts, sourcing administrative, IT and accounting support, and transferring all the data, records, ownership, and funds into the new entity. This was followed by establishing and documenting new systems and processes. I want to thank all of those involved in that process, it could not have happened without each of you.

After the first six months of operation, we have:

- strengthened and confirmed our presence and relationships at a national level, reflected by us being on a range of national committees and included in key consultation activities;
- a committed, engaged, diverse and growing membership;
- established a Consumer Advisory Group (CAG) which is integrated into our structure;
- appointed a highly qualified and capable CEO (Erin Evans commenced on 1 July 2024);
- a strong reputation and network across the sector;
- a solid membership pipeline;
- a sound cash position; and
- established and documented systems and processes.

At our member meetings we heard from:

- CAG members about their experiences and expectations, including how they wish to engage;
- new InGeNA members about their work;
- SING <https://singaustralia.org/> participants about the impact of our sponsorship; and
- from various state governments about their genomics initiatives and priorities.

We have held in person member get-togethers and attended a range of industry events. We are proud to have been part of the successful campaign for a legislative ban on genetic discrimination by life insurers.

After two years leading InGeNA Limited through a period of significant change, I will be stepping down as Chair. InGeNA is in a strong position to build upon its solid foundations, and to leverage the work already undertaken and the relationships developed to continue working towards embedding genomics in our health system to benefit Australians.

I want to thank our Deputy Chair, the rest of the Board, and others (members and people from across the sector) for the support and wise advice you have provided during my tenure. I continue to have a strong commitment to and passion for the difference genomics can make and look forward to seeing InGeNA's continued contribution to making this happen.

Kathy Campbell
October 2024

CEO REPORT

I am delighted to present my first report as CEO of InGeNA, having joined the organisation on 1 July 2024. From day one, I have been impressed by the warm welcome extended to me by our highly engaged members and the unwavering support of our dedicated board. This sense of community and collaboration has been integral to InGeNA's success and will continue to drive us forward in the year ahead.

Our clear and focused strategy serves as the foundation for our ambitious goals as we embark on this next chapter. Over the coming year, we will concentrate on several key areas that are essential for advancing genomics and ensuring InGeNA's continued growth and impact:



Dr Erin Evans

- 1. Policy Leadership:** A core focus will be advancing InGeNA's policy positions to ensure genomics remains a national priority. We will work closely with stakeholders to provide input into the new National Genomics Framework, which will shape the future of genomics in Australia.
- 2. Activating Our Strategy:** Moving from strategy to execution, we will translate our long-term vision into a roadmap, outlining specific milestones and timelines. This will ensure we remain on track to achieve our goals while being adaptable to emerging opportunities.
- 3. Building Relationships and Influence:** Strengthening and expanding our relationships at both national and state levels will be a key priority. By forging stronger connections with government bodies, industry leaders, and other stakeholders, we aim to enhance our influence and ensure that genomics remains at the forefront of healthcare discussions.

continued..

- 4. Collaborative Partnerships:** Collaboration is at the heart of InGeNA's success. We will continue working with partners across sectors to foster innovation, enhance the integration of genomics into healthcare, and amplify our collective impact.
- 5. Leveraging Past Achievements:** InGeNA has achieved significant progress to date, and we will build on this foundation. By leveraging the great work already done, we will accelerate our initiatives and create more value for our members and the broader genomics ecosystem.
- 6. Membership Growth and Financial Sustainability:** To ensure InGeNA's long-term sustainability, we will focus on diversifying and growing our membership base. This will not only secure our financial future but also expand our reach, bringing in new perspectives and expertise to further enrich our work.

I want to express my gratitude to our outgoing Chair for her leadership of InGeNA and navigating the transformation that has positioned the organisation strongly for growth.

Thank you for your continued support and commitment to InGeNA. I am confident that the period ahead holds tremendous promise for InGeNA, and I look forward to working closely with our members, partners, and the board to achieve our shared goals. Together, we will continue to drive the adoption of genomics in Australia, positioning InGeNA as a leader in this rapidly evolving field.

Dr. Erin Evans

CEO, InGeNA Limited

INGENA INAUGURAL BOARD



Kathryn Campbell
Independent Chair



Susan McKean
Independent Deputy Chair



Mark Grosser
Member Elected Director



Robert McBride
Member Elected Director



Diana Nielson
Member Elected Director



Carl Stubbings
Member Elected Director

[View Board Members Bios here](#)


INGENA CONSUMER ADVISORY GROUP



Monica Ferrie
Chair



Agnes Nsofwa
Member



Sarah Powell
Member



Caitlin Howley
Member



Julie Cini
Member



Felicity Johnson
Member

[View CAG Bios here](#)

INGENA MEMBERS

As at 30 June 2024



GeneS

New Members as at 1 November 2024



SUMMARY FINANCIAL REPORT

*A full set of Statutory Accounts
has been made available to members.*



Industry Genomics Network Alliance

ANNUAL REPORT 2023 - 2024

(PART YEAR,
1 JANUARY 2024 TO 30 JUNE 2024)

CONTACT US

info@ingena.org.au

www.ingena.org.au